Briacell Therapeutics Corp. Common Shares
$3.93
$0.37 (+10.39%)
$3.57Day Range$3.95
Key Statistics
Market Cap
$30.97M
Shares Outstanding
8.7M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Sep 5, 2023
Round Lot
100
Locale
US
Trading Data
Day Open
$3.57
Day High
$3.95
Day Low
$3.57
Volume
192.2K
VWAP
$3.81
Prev Close
$3.56
Transactions
--
Acc. Volume
--
About Briacell Therapeutics Corp. Common Shares
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
PHARMACEUTICAL PREPARATIONSSIC 28344 employees3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR, WEST VANCOUVER, A1, V7T 2X1(604) 921-1810IPO Sep 5, 2023US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001610820
- Composite FIGI
- BBG0018783B6
- Share Class FIGI
- BBG001SMHR46
- Ticker Root
- BCTX
- SIC Code
- 2834
About Briacell Therapeutics Corp. Common Shares (BCTX) Stock
Briacell Therapeutics Corp. Common Shares (BCTX) closed the 2026-09-17 session at $3.93, up 10.39% versus the previous close (+0.37). The stock opened at $3.57 and traded between $3.57 and $3.95 during that session. Session trading volume was 192K shares. The volume-weighted average price (VWAP) is $3.81.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.
Briacell Therapeutics Corp. Common Shares has a market capitalization of $31.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. BCTX is listed on the XNAS exchange. The company employs approximately 4 people. Briacell Therapeutics Corp. Common Shares is headquartered in WEST VANCOUVER, A1. The recorded listing date is 2023-09-05.
On this page you can find market BCTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.